Read this report today, it will make you fell better. Today, the company announced today that it has signed agreements to purchase shares of its Series E convertible preferred stock pursuant to a registered direct offering to institutional investors, representing gross proceeds to ADVENTRX of approximately $19 million dollars.
In a huge tell about how the company is feeling about their chances, ADVENTRX says it plans to use the net proceeds from the offering to fund activities relating to the commercial launch of ANX-530, including acquiring or developing sales, marketing and distribution capabilities and the associated regulatory compliance infrastructure, and to continue the development of ANX-514 in the United States.
Compared to most biotechs with this much upside, ADVENTRX has a relatively low number of outstanding shares and a very small market cap.
They have no debt and at now least 24 months of cash on hand.
Also, ADVENTRX's costs do not include typical high dollar expensive clinical studies. ANX's clinical studies are understandably much, much lower.
In short, ANX is taking high profit drugs, improving delivery and presenting investors with a tremendous buying opportunity.
I believe this is a very solid company with an excellent chance of price share appreciation both in the very short and long term. Mike Burns is a former investment advisor with First Albany and Smith Barney. He now works in the pharmaceutical industry and is a contributor to BioMedReports. Disclosure: Long ANX
Copyright 2010 BAYSTREET NEWSWIRE